ANIX [NASD]
Anixa Biosciences, Inc.
Index- P/E- EPS (ttm)-0.49 Insider Own4.40% Shs Outstand30.12M Perf Week6.33%
Market Cap109.04M Forward P/E- EPS next Y-0.61 Insider Trans4.78% Shs Float28.55M Perf Month31.72%
Income-14.60M PEG- EPS next Q-0.13 Inst Own11.00% Short Float1.77% Perf Quarter32.71%
Sales-0.00M P/S- EPS this Y-0.60% Inst Trans-4.04% Short Ratio7.34 Perf Half Y-9.49%
Book/sh1.13 P/B3.12 EPS next Y-17.30% ROA-39.60% Target Price11.00 Perf Year-12.41%
Cash/sh1.12 P/C3.16 EPS next 5Y- ROE-40.60% 52W Range2.30 - 5.87 Perf YTD18.86%
Dividend- P/FCF- EPS past 5Y4.60% ROI-37.10% 52W High-39.86% Beta1.39
Dividend %- Quick Ratio19.60 Sales past 5Y11.30% Gross Margin- 52W Low53.48% ATR0.30
Employees4 Current Ratio19.60 Sales Q/Q- Oper. Margin- RSI (14)60.85 Volatility10.74% 10.19%
OptionableYes Debt/Eq0.00 EPS Q/Q-44.80% Profit Margin- Rel Volume1.57 Prev Close3.29
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume68.91K Price3.53
Recom2.00 SMA207.89% SMA5021.01% SMA200-3.12% Volume108,079 Change7.46%
Apr-12-21Initiated H.C. Wainwright Buy $11
May-18-22 06:16AM  
May-05-22 08:30AM  
May-02-22 09:40AM  
Apr-28-22 08:30AM  
Apr-06-22 08:30AM  
Mar-30-22 12:45PM  
Mar-17-22 08:30AM  
Jan-25-22 08:30AM  
Jan-24-22 08:30AM  
Dec-16-21 08:30AM  
Dec-09-21 04:38AM  
Dec-08-21 07:47AM  
Dec-07-21 08:30AM  
Oct-26-21 08:35AM  
Oct-06-21 08:30AM  
Oct-01-21 08:30AM  
Sep-27-21 02:01PM  
Sep-14-21 08:31AM  
Sep-08-21 08:30AM  
Sep-07-21 08:30AM  
Aug-31-21 11:08AM  
Aug-30-21 08:30AM  
Aug-25-21 03:14PM  
08:30AM  
Aug-23-21 08:30AM  
Aug-18-21 08:30AM  
Jun-12-21 03:12AM  
May-26-21 08:30AM  
May-20-21 08:30AM  
May-07-21 08:30AM  
Apr-21-21 02:54PM  
Apr-19-21 12:58PM  
08:30AM  
Apr-14-21 09:13PM  
Apr-05-21 08:30AM  
Mar-22-21 10:00PM  
05:18PM  
08:30AM  
Mar-12-21 08:30AM  
Mar-08-21 08:30AM  
Mar-04-21 08:30AM  
Feb-25-21 08:30AM  
Feb-16-21 08:30AM  
Jan-13-21 08:30AM  
Jan-05-21 08:30AM  
Dec-21-20 08:30AM  
Dec-14-20 09:00AM  
Dec-11-20 08:45AM  
Dec-01-20 09:00AM  
Nov-23-20 08:30AM  
Oct-27-20 08:00AM  
Oct-25-20 08:30AM  
Sep-14-20 11:43AM  
Sep-08-20 08:00AM  
Aug-13-20 09:00AM  
Jul-28-20 09:00AM  
Jul-20-20 09:00AM  
Jul-10-20 07:25AM  
07:00AM  
Jul-06-20 09:00AM  
Jul-02-20 05:00PM  
Jun-01-20 08:30AM  
May-04-20 06:45AM  
Apr-28-20 06:32AM  
Apr-23-20 07:00AM  
Apr-21-20 06:00PM  
Apr-20-20 06:30AM  
Mar-23-20 06:28AM  
Mar-02-20 07:00AM  
Feb-12-20 07:00AM  
Feb-11-20 07:16AM  
Jan-06-20 07:00AM  
Jan-02-20 05:25AM  
Dec-23-19 07:00AM  
Dec-16-19 06:45AM  
Dec-13-19 05:45PM  
06:45AM  
Dec-02-19 07:00AM  
Nov-26-19 07:00AM  
Nov-22-19 07:00AM  
Nov-20-19 07:00AM  
Nov-07-19 07:00AM  
Nov-05-19 07:00AM  
Nov-03-19 07:38AM  
Oct-28-19 07:00AM  
Oct-25-19 07:00AM  
Oct-22-19 07:00AM  
Oct-15-19 07:00AM  
Oct-10-19 07:00AM  
Sep-23-19 07:00AM  
Sep-19-19 07:53AM  
07:00AM  
Sep-16-19 07:00AM  
Aug-26-19 07:00AM  
Jul-29-19 07:00AM  
Jul-24-19 07:00AM  
Jul-23-19 01:22PM  
Jul-22-19 07:00AM  
Jul-17-19 12:25PM  
07:00AM  
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Titterton Lewis H jrDirectorApr 26Buy2.7910,00027,900988,070Apr 27 10:01 AM
Catelani MichaelPresidentApr 21Buy2.665,50014,63018,135Apr 22 09:50 AM
Catelani MichaelPresidentApr 20Buy2.532,5096,34812,635Apr 21 11:28 AM
Titterton Lewis H jrDirectorJan 12Buy3.285,00016,400978,070Jan 13 10:23 AM
Titterton Lewis H jrDirectorJan 11Buy3.202,0006,400973,070Jan 12 09:54 AM
Titterton Lewis H jrDirectorJan 10Buy3.086,00018,480971,070Jan 11 09:21 AM
Titterton Lewis H jrDirectorJan 07Buy3.0811,00033,880965,070Jan 10 09:36 AM
KUMAR AMITChief Executive OfficerJan 07Buy3.0020,00060,000314,000Jan 07 10:32 AM
Titterton Lewis H jrDirectorOct 29Buy4.7618,24486,841954,070Nov 01 01:32 PM
KUMAR AMITChief Executive OfficerOct 29Buy4.772,0009,540294,000Nov 01 11:05 AM
Titterton Lewis H jrDirectorJul 26Buy4.2130,000126,300935,826Jul 28 09:00 AM
KUMAR AMITChief Executive OfficerJul 23Buy4.285,00021,400292,000Jul 27 01:08 PM
Baskies Arnold MDirectorJul 23Buy4.3319,00082,270100,000Jul 27 09:56 AM
KUMAR AMITChief Executive OfficerJul 16Buy3.9410,00039,400287,000Jul 20 09:00 AM
Titterton Lewis H jrDirectorJul 16Buy4.0710,00040,700905,826Jul 19 12:39 PM
Baskies Arnold MDirectorJul 15Buy3.9020,00078,00081,000Jul 16 11:22 AM
Titterton Lewis H jrDirectorJul 15Buy3.652,2008,030895,826Jul 19 12:39 PM
Gottschalk EmilyDirectorJul 15Buy3.9620,06579,45745,665Jul 16 12:45 PM
Titterton Lewis H jrDirectorJul 14Buy3.7223,30086,676893,626Jul 15 11:19 AM